← Leaderboards
Christopher D Pilcher
University Of North Carolina Chapel Hill
$6,871,284
Attributed
$6,871,284
Total exposure
14
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $945K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,871,284 · 14
By mechanism
R01$4,736,406 · 2
M01$824,725 · 10
R34$693,203 · 1
K23$616,950 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Charles Michael Van Der Horst$17,688,631
- William C Miller$15,807,976
- Deborah A O'Brien$7,963,395
- Barry L Whitsel$2,302,970
- Jonathan T Hamm$7,316
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsClinical ResearchHuman SubjectHuman Therapy EvaluationAids TherapyCombination ChemotherapyPatient Oriented ResearchTransmission ProcessAntiaids AgentBaseLinkAffectGenital SystemDiagnosisAntiviral AgentsCost EffectivenessT LymphocyteLongitudinal Human StudyLeukocyte Activation /TransformationPreventDrug Screening /EvaluationImmunotherapyColony Stimulating FactorBlood
Grant awards (40)
Host Factors Influencing HIV Viral Load and Infectivity in Semen$612,052
R01 · FY2016 · HD · contact PI
Host Factors Influencing HIV Viral Load and Infectivity in Semen$608,818
R01 · FY2015 · HD · contact PI
Host Factors Influencing HIV Viral Load and Infectivity in Semen$616,287
R01 · FY2014 · HD · contact PI
A Pilot of Intervention to Promote Acute HIV Testing by Ambulatory Care Providers$197,500
R34 · FY2014 · MH · contact PI
Host Factors Influencing HIV Viral Load and Infectivity in Semen$605,895
R01 · FY2013 · HD · contact PI
A Pilot of Intervention to Promote Acute HIV Testing by Ambulatory Care Providers$339,120
R34 · FY2013 · MH · contact PI
Host Factors Influencing HIV Viral Load and Infectivity in Semen$662,955
R01 · FY2012 · HD · contact PI
A Pilot of Intervention to Promote Acute HIV Testing by Ambulatory Care Providers$156,583
R34 · FY2012 · MH · contact PI
Targeting Acute HIV$328,545
R01 · FY2007 · MH · contact PI
Targeting Acute HIV$223,536
R01 · FY2006 · MH · contact PI
Targeting Acute HIV$107,222
R01 · FY2006 · MH · contact PI
THREE PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$64,422
M01 · FY2006 · RR · contact PI
ONCE DAILY REGIMEN OF DIDANOSINE, TENOFOVIR AND EFAVIRENZ$38,252
M01 · FY2006 · RR · contact PI
LAMIVUDINE PLUS STAVUDINE PLUS ABACAVIR PLUS AMPRENAVIR/RITONAVER$38,252
M01 · FY2006 · RR · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM$6,040
M01 · FY2006 · RR · contact PI
ACTG A5217 - TREATMENT VS NO TREATMENT IN NEWLY INFECTED HIV-1 SUBJECTS$3,020
M01 · FY2006 · RR · contact PI
Targeting Acute HIV$327,532
R01 · FY2005 · MH
THREE PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$202,913
M01 · FY2005 · RR
LAMIVUDINE PLUS STAVUDINE PLUS ABACAVIR PLUS AMPRENAVIR/RITONAVER$51,346
M01 · FY2005 · RR
IMMUNOLOGIC AND VIROLOGIC INDICES IN TWO AGE-DIFFERENTIATED COHORTS OF HIV$20,703
M01 · FY2005 · RR
HAART-INDUCED IMMUNE RESTORATION WITH THE USE OF CYCLOSPORINE$7,453
M01 · FY2005 · RR
VACCINE-INDUCED HELPER &CTL RESPONSES TO CONTROL VIREMIA IN THE ABSENSE OF ART$2,484
M01 · FY2005 · RR
ONCE DAILY REGIMEN OF DIDANOSINE, TENOFOVIR AND EFAVIRENZ$1,657
M01 · FY2005 · RR
Targeting Acute HIV$316,032
R01 · FY2004 · MH
THREE PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$257,467
M01 · FY2004 · RR
CYTOREDUCTIVE CHEMOTHERAPY TARGETING HIV RESERVOIRS$123,390
K23 · FY2004 · AI
HAART-Induced Immune Restoration with the Use of Cyclosporine$41,987
M01 · FY2004 · RR
IMMUNOLOGIC AND VIROLOGIC INDICES IN TWO AGE-DIFFERENTIATED COHORTS OF HIV$27,728
M01 · FY2004 · RR
VACCINE-INDUCED HELPER &CTL RESPONSES TO CONTROL VIREMIA IN THE ABSENSE OF ART$25,351
M01 · FY2004 · RR
LAMIVUDINE PLUS STAVUDINE PLUS ABACAVIR PLUS AMPRENAVIR/RITONAVER$22,974
M01 · FY2004 · RR
Restarting Therapy with Potent Antiretroviral Therapy +/- Interleukin-2$11,091
M01 · FY2004 · RR
AUGMENTATION OF HIV-SPECIFIC HELPER AND CTL RESPONSES$1,585
M01 · FY2004 · RR
Targeting Acute HIV$327,532
R01 · FY2003 · MH
CYTOREDUCTIVE CHEMOTHERAPY TARGETING HIV RESERVOIRS$123,390
K23 · FY2003 · AI
CYTOREDUCTIVE CHEMOTHERAPY TARGETING HIV RESERVOIRS$123,390
K23 · FY2002 · AI
CYTOREDUCTIVE CHEMOTHERAPY TARGETING HIV RESERVOIRS$123,390
K23 · FY2001 · AI
CYTOREDUCTIVE CHEMOTHERAPY TARGETING HIV RESERVOIRS$123,390
K23 · FY2000 · AI
ANTIVIRAL ACTIVITY OF T-1249 IN HIV-1 INFECTED ADULTS$0
M01 · FY2000 · RR
ANTIVIRAL ACTIVITY OF T-1249 IN HIV-1 INFECTED ADULTS$0
M01 · FY2000 · RR
ANTIVIRAL ACTIVITY OF T-1249 IN HIV-1 INFECTED ADULTS$0
M01 · FY2000 · RR